Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5672391 | 0.89 | KDM4E (0.49) | FAAHLMNADRD3KDM4EHRH3 | |
| SCHEMBL6750841 | 0.81 | FAAH (0.39) | FAAHLMNADRD3KCNH2ALDH1A1 | |
| SCHEMBL5669920 | 0.81 | MCHR1 (0.48) | FAAHKCNH2KDM4EHRH3APP | |
| SCHEMBL28757287 | 0.78 | LTA4H (0.48) | LMNADRD3HRH3APPDRD2 | |
| SCHEMBL6750836 | 0.76 | HRH3 (0.58) | KDM4EHRH3APPALDH1A1SMN1; SMN2 | |
| SCHEMBL5670771 | 0.76 | HRH3 (0.43) | FAAHLMNAKDM4EPOLBHRH3 | |
| SCHEMBL5406373 | 0.71 | ALDH1A1 (0.50) | LMNAKDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL5397992 | 0.70 | ALDH1A1 (0.48) | LMNAKDM4EPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL6750846 | 0.69 | SLC6A3 (0.41) | FAAH | |
| SCHEMBL5672388 | 0.69 | LTA4H (0.43) | KDM4EPOLBALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | claimed |
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | EURO-CELTIQUE S.A. | 2004-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097569-A1 | Aryl substituted hydantoin compounds and their use as sodium channel blockers | SCN1A, CACNA1S, SCN1B | FAAH 254/4885LMNA 372/4885DRD3 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.